MEDI-7510

Analyst Outlook

MEDI-7510 (AstraZeneca) is a Phase II intramuscular vaccine consisting of soluble respiratory

syncytial virus (RSV) fusion (F) protein with a glucopyranosyl lipid adjuvant (GLA). MEDI-7510 is being

targeted at the elderly population, which is in contrast to the company’s portfolio of live-attenuated

vaccines for which it is pursuing approval for use in infants. The 2015 success of Novavax’s rival RSV F

vaccine in a Phase II proof-of-efficacy study partially de-risks MEDI-7510’s development program, as

both vaccines have similar designs and aim to elicit palivizumab-competing antibody (PCA) responses

against the RSV F protein. However, the promising efficacy data also raise the bar for MEDI-7510, and

provide a standard against which MEDI-7510 must improve if it aims to capture significant market

share from its more advanced rival. Datamonitor Healthcare believes that MEDI-7510’s inclusion of

GLA could allow it stimulate superior T-helper type 1 (TH1) cellular immunity compared to Novavax’s

vaccine, but it is unclear whether the stimulation of a broader immune response will translate into

significantly improved protection.

Drug Overview

MEDI-7510 is a Phase II intramuscular vaccine comprising RSV F protein with a GLA. The vaccine is

being developed for the prevention of severe disease caused by RSV in adults aged over 60 years.

AstraZeneca has formed an exclusive agreement with Immune Design to use the latter’s GLA – a

synthetic molecule licensed from Immune Design’s GLAAS discovery platform – in vaccines for RSV

and two other undisclosed indications (Immune Design, 2014).